ONS - オンコバイオロジックス （Oncobiologics Inc.） オンコバイオロジックスONSのチャート
ONSの企業情報
| symbol | ONS |
|---|---|
| 会社名 | Oncobiologics Inc （オンコバイオロジックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Oncobiologics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying developing manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate ONS-1045 is a bevacizumab (Avastin) biosimilar. The Company''s other preclinical product candidate ONS-1050 a trastuzumab (Herceptin) biosimilar interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva) which is a human mAb. Its other biosimilar product ONS-1055 is a biosimilar to cetuximab (Erbitux). オンコバイオロジックスは米国のバイオ医薬品企業。免疫学と腫瘍学の疾病領域において、モノクロ―ナル抗体に焦点を当てたバイオ後続医薬品の識別・開発・製造・商品化に従事する。先行バイオ医薬品のアダリムバム(ヒュミラ)やベバシズマブ(アバスチン)などのバイオシミラ―を開発中。本社はニュ―ジャ―ジ―州クランブリ―。 Oncobiologics Inc is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing, manufacturing and commercializing complex biosimilar therapeutics in the disease areas of immunology and oncology. |
| 本社所在地 | 7 Clarke Drive Cranbury NJ 08512 USA |
| 代表者氏名 | Ralph H. Thurman Ralph H. Thurman |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 609-619-3990 |
| 設立年月日 | 40179 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 89人 |
| url | www.oncobiologics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ons |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -16.93292 |
| 終値（lastsale） | 0.94 |
| 時価総額（marketcap） | 67866559.92 |
| 時価総額 | 時価総額（百万ドル） 64.25664 |
| 売上高 | 売上高（百万ドル） 5.21777 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 78.24689 |
| 当期純利益 | 当期純利益（百万ドル） -42.92444 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Oncobiologics Inc revenues increased from $909K to $2.3M. Net loss applicable to common stockholders increased 9% to $35.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Change in fair value of warrant liabilit decrease of 94% to $226K (income). |
ONSのテクニカル分析
ONSのニュース
Oncobiologics reports Q3 results 2018-08-14
Oncobiologics (NASDAQ: ONS ): Q3 EPS of -$0.26 More news on: Oncobiologics, Earnings news and commentary, Healthcare stocks news, , Read more …